Teniposide in recurrent or advanced cervical carcinoma: a phase II trial in patients not previously treated with cytotoxic therapy.

Abstract

Thirty-two patients with advanced or recurrent cervical cancer were entered into this study of single-agent teniposide as first-line chemotherapy at a dose of 100 mg/m2 intravenously on Days 1-3 every 3 weeks. Of these patients, 7 (22%) had a partial response to therapy; no patient had a complete response. Median time to treatment failure was 13 weeks [95% confidence limits (CL): 10-21 weeks] and median survival was 28 weeks (95% CL: 14-43 weeks). Toxicity was moderate. Leukopenia and thrombocytopenia (WHO grade 3 or 4) was noted in 9 patients and 1 patient, respectively. Nausea and vomiting were mild. Seventy-five percent had alopecia requiring a wig. There were no treatment-related deaths. This study indicates that teniposide has some, although limited, activity in cervical cancer.

• Authors: P Pfeiffer, S Cold, K Bertelsen, J Panduro, E Sandberg, C Rose
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 37 Issue 2 Pg. 230-3 (May 1990) ISSN: 0090-8258 [Print] United States
• PMID: 2344968 (Publication Type: Journal Article)

Chemical References

• Teniposide
• Podophyllotoxin

Topics

• Adult
• Aged
• Carcinoma (drug therapy, mortality)
• Drug Evaluation
• Female
• Humans
• Leukopenia (chemically induced)
• Middle Aged
• Neoplasm Recurrence, Local
• Podophyllotoxin (analogs & derivatives)
• Survival
• Teniposide (adverse effects, therapeutic use)
• Uterine Cervical Neoplasms (drug therapy, mortality)